German Government Pushes for Strengthened Pharmaceutical Industry
Philipp Amthor emphasizes the importance of a new location clause to boost domestic production and innovation.
Philipp Amthor, the State Minister for Federal-State Relations, addressed the annual conference of the industry association Pharma Deutschland in Berlin this week. Representing the federal government, Amthor highlighted the strategic importance of the pharmaceutical sector, framing it as a vital economic driver rather than merely a cost burden on the national health insurance system.
The appearance by the 34-year-old politician came as a last-minute replacement for Nina Warken, the head of the Federal Chancellery, who was unable to attend due to ongoing budget negotiations. Amthor used the platform to convey greetings from Chancellor Friedrich Merz and to reaffirm the government's commitment to fostering a competitive environment for drug manufacturers.
Central to the discussion was the proposal of a 'location clause,' which would grant pharmaceutical companies exemptions from certain mandatory price discounts if they meet specific criteria, such as maintaining collective bargaining agreements and investing in research and production within Germany. Amthor argued that failing to make such decisions would be detrimental to the country's industrial future, stating, 'Not deciding is a decision against Germany.'
Health Minister Carsten Linnemann, also speaking at the event, expressed support for the concept of a location clause but drew a firm line regarding how it should be financed. Linnemann insisted that industrial policy must be funded through the general federal budget rather than relying on the contributions of those enrolled in the statutory health insurance system. He cautioned against undermining the existing savings package designed to keep health insurance premiums stable.
Amthor acknowledged the complex challenges facing the industry, including international trade pressures and the high costs associated with developing innovative therapies. He emphasized that the government aims to balance affordable healthcare access with the necessity of supporting a high-growth sector. 'We are facing the challenge of launching good and affordable care, making innovative medicines available to everyone, without blowing the cost framework of the statutory health insurance,' Amthor noted.
Beyond financial policy, the discussion touched on the digital transformation of the healthcare sector. Amthor expressed a desire for Germany to move beyond its reputation for strict data protection to become a leader in data utilization. He pointed to the Law for Data and Digital Innovations in Healthcare as a key step in leveraging high-quality supply data to fuel future medical breakthroughs.
Jörg Wieczorek, the chairman of Pharma Deutschland, welcomed the government's focus on the sector, describing the location clause as a critical factor for the future of the German pharmaceutical landscape. He urged the administration to move quickly from political signals to concrete policy implementation to secure more investment and production capacity within the country.